<VariationArchive RecordType="classified" VariationID="5962" VariationName="NM_006996.3(SLC19A2):c.429_430del (p.Ile145fs)" VariationType="Deletion" Accession="VCV000005962" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-04-25" DateCreated="2017-11-25" MostRecentSubmission="2017-11-25">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="21001" VariationID="5962">
      <GeneList>
        <Gene Symbol="SLC19A2" FullName="solute carrier family 19 member 2" GeneID="10560" HGNC_ID="HGNC:10938" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>1q24.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="169463909" stop="169485970" display_start="169463909" display_stop="169485970" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="169433146" stop="169455207" display_start="169433146" display_stop="169455207" Strand="-" />
          </Location>
          <OMIM>603941</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_006996.3(SLC19A2):c.429_430del (p.Ile145fs)</Name>
      <CanonicalSPDI>NC_000001.11:169477531:AA:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>1q24.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="169477532" stop="169477533" display_start="169477532" display_stop="169477533" variantLength="2" positionVCF="169477531" referenceAlleleVCF="TAA" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="169446770" stop="169446771" display_start="169446770" display_stop="169446771" variantLength="2" positionVCF="169446769" referenceAlleleVCF="TAA" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>I145fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.169446770_169446771del" Assembly="GRCh37">
            <Expression>NC_000001.10:g.169446770_169446771del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.11" sequenceAccession="NC_000001" sequenceVersion="11" change="g.169477532_169477533del" Assembly="GRCh38">
            <Expression>NC_000001.11:g.169477532_169477533del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008255.1" sequenceAccession="NG_008255" sequenceVersion="1" change="g.13438_13439del">
            <Expression>NG_008255.1:g.13438_13439del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_006996.3" sequenceAccession="NM_006996" sequenceVersion="3" change="c.429_430del" MANESelect="true">
            <Expression>NM_006996.3:c.429_430del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_008927.1" sequenceAccession="NP_008927" sequenceVersion="1" change="p.Ile145fs">
            <Expression>NP_008927.1:p.Ile145fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001319667.1" sequenceAccession="NM_001319667" sequenceVersion="1" change="c.205-7347_205-7346del">
            <Expression>NM_001319667.1:c.205-7347_205-7346del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="603941.0008" DB="OMIM" />
        <XRef Type="rs" ID="1571537879" DB="dbSNP" />
      </XRefList>
      <Comment DataSource="ClinGen" Type="public">ClinGen staff contributed the HGVS expression for this variant.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_006996.3(SLC19A2):c.429_430del (p.Ile145fs) AND Megaloblastic anemia, thiamine-responsive, with diabetes mellitus and sensorineural deafness" Accession="RCV000006326" Version="3">
        <ClassifiedConditionList TraitSetID="1649">
          <ClassifiedCondition DB="MedGen" ID="C0342287">Megaloblastic anemia, thiamine-responsive, with diabetes mellitus and sensorineural deafness</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1999-07-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="1999-07-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-11-25" MostRecentSubmission="2017-11-25">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10391223</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1649" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4256" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Megaloblastic anemia, thiamine-responsive, with diabetes mellitus and sensorineural deafness</ElementValue>
                <XRef ID="Thiamine+responsive+megaloblastic+anemia+syndrome/7055" DB="Genetic Alliance" />
                <XRef ID="237617006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">THIAMINE METABOLISM DYSFUNCTION SYNDROME 1 (MEGALOBLASTIC ANEMIA, DIABETES MELLITUS, AND DEAFNESS TYPE)</ElementValue>
                <XRef Type="MIM" ID="249270" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Thiamine-responsive anemia syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Rogers syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Thiamine-responsive myelodysplasia</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">TRMA</ElementValue>
                <XRef Type="MIM" ID="249270" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">THMD1</ElementValue>
                <XRef Type="MIM" ID="249270" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Thiamine-responsive megaloblastic anemia syndrome (TRMA) is characterized by megaloblastic anemia, progressive sensorineural hearing loss, and diabetes mellitus. Onset of megaloblastic anemia occurs between infancy and adolescence. The anemia is corrected with thiamine treatment, but the red cells remain macrocytic, and anemia can recur when treatment is withdrawn. Progressive sensorineural hearing loss has generally been early and can be detected in toddlers; hearing loss is irreversible and may not be prevented by thiamine treatment. The diabetes mellitus is non-type I in nature, with age of onset from infancy to adolescence. Thiamine treatment may delay onset of diabetes in some individuals.</Attribute>
                <XRef ID="NBK1282" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301459</ID>
                <ID Source="BookShelf">NBK1282</ID>
              </Citation>
              <XRef ID="49827" DB="Orphanet" />
              <XRef ID="C0342287" DB="MedGen" />
              <XRef ID="MONDO:0009575" DB="MONDO" />
              <XRef Type="MIM" ID="249270" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="26508" SubmissionDate="2017-11-22" DateLastUpdated="2017-11-25" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="603941.0008_THIAMINE-RESPONSIVE MEGALOBLASTIC ANEMIA SYNDROME" title="SLC19A2, 2-BP DEL, 429TT_THIAMINE-RESPONSIVE MEGALOBLASTIC ANEMIA SYNDROME" />
        <ClinVarAccession Accession="SCV000026508" DateUpdated="2017-11-25" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1999-07-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In affected members of an Iranian family with thiamine-responsive megaloblastic anemia syndrome (TRMA; 249270), Diaz et al. (1999) identified a 2-bp deletion involving 429T and 430T of the SLC19A2 gene. Three affected members of the family were studied and found to be homozygous. Two sets of parents and 1 unaffected sib were heterozygous for the mutation.</Attribute>
              <Citation>
                <ID Source="PubMed">10391223</ID>
              </Citation>
              <XRef DB="OMIM" ID="249270" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC19A2" />
          </GeneList>
          <Name>SLC19A2, 2-BP DEL, 429TT</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">2-BP DEL, 429TT</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="603941.0008" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">THIAMINE-RESPONSIVE MEGALOBLASTIC ANEMIA SYNDROME</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="26508" TraitType="Disease" MappingType="Name" MappingValue="THIAMINE-RESPONSIVE MEGALOBLASTIC ANEMIA SYNDROME" MappingRef="Preferred">
        <MedGen CUI="C0342287" Name="Megaloblastic anemia, thiamine-responsive, with diabetes mellitus and sensorineural deafness" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

